Confounding by indication and channeling over time: The risks of β2- agonists

American Journal of Epidemiology

Volumn 144, Issue 12, 1996, Pages 1161-1169

  Blais, Lucie ^a,b   Ernst, Pierre ^a,c   Suissa, Samy ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

asthma; bronchodilator agents; cohort studies; confounding factors (epidemiology); epidemiologic methods

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FENOTEROL; IPRATROPIUM BROMIDE; SALBUTAMOL;

ADOLESCENT; ADULT; ARTICLE; ASTHMA; CASE CONTROL STUDY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRESCRIPTION;

EID: 0029834111     PISSN: 00029262     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.aje.a008895     Document Type: Article

References (37)

1. Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983;2:267-71.
2. Strom BL, Melmon KL, Miettinen OS. Post-marketing studies of drug efficacy: Why? Am J Med 1985;78:475-80.
3. Strom BL, Miettinen OS, Melmon KL. Post-marketing studies of drug efficacy: How? Am J Med 1984;77:703-8.
4. Horwitz RI, Spitzer W, Buist S, et al. Clinical complexity and epidemiologic uncertainty in case-control research. Fenoterol and asthma management. Chest 1991;100:1586-91.
5. Spitzer WO, Suissa S, Ernst P, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med 1992;326:501-6.
6. McFadden ER Jr, Perspectives in beta 2-agonist therapy: vox clamantis in deserto vel lux in tenebris? J Allergy Clin Immunol 1995;95:641-51.
7. Pearce N, Beasley R, Crane J, et al. End of the New Zealand asthma mortality epidemic. Lancet 1995;345:41-4.
8. Burrows B, Lebowitz MD. The beta-agonist dilemma. (Editorial). N Engl J Med 1992;326:560-1.
9. Gottlieb DJ, Celli BR. Beta-agonists and death from asthma. (Letter). N Engl J Med 1992;327:355.
10. Staudinger HW, Haas JF. Beta-agonists and death from asthma. (Letter). N Engl J Med 1992;327:355.
11. Sears MR. Use of fenoterol and severity of asthma. (Letter). N Z Med J 1991;104:192.
12. Petri H, Urquhart J. Channeling bias in the interpretation of drug effects. Stat Med 1991;10:577-81.
13. Petri H, Urquhart J, Herings R, et al. Characteristics of patients prescribed three different inhalational beta-2 agonists: an example of the channeling phenomenon. Post Marketing Surveillance 1991;5:57-66.
14. Beasley R, Burgess C, Pearce N, et al. Confounding by severity does not explain the association between fenoterol and asthma death. Clin Exp Allergy 1995;24:660-8.
15. Kelsey JL, Thompson WD, Evans AS. Methods in observational epidemiology. New York: Oxford University Press, 1986.
16. National Asthma Education Program. Guidelines for the diagnosis and management of asthma. Expert Panel report. Bethesda: National Institutes of Health, 1991. (DHHS publication no. (PHS) 91-3042).
17. International Asthma Management Project, National Heart, Lung, and Blood Institute. International consensus report on diagnosis and treatment of asthma. Eur Respir J 1992;5:601-41.
18. Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax 1991;46:105-11.
19. Woodman K, Pearce N, Beasley R, et al. Albuterol and deaths from asthma in New Zealand from 1969 to 1976: a case-control study. Clin Pharmacol Ther 1992;51:566-71.
20. Crane J, Pearce N, Burgess C, et al. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int J Epidemiol 1992;21:737-44.
21. Janson-Bjerklie S, Ferketich S, Benner P, et al. Clinical markers of asthma severity and risk: importance of subjective as well as objective factors. Heart Lung 1992;21:265-72.
22. Bolliger CT, Fourie PR, Kotze D, et al. Relation of measures of asthma severity and response to treatment to outcome in acute severe asthma. Thorax 1992;47:943-7.
23. Roberts SJ, Bateman DN. Which patients are prescribed inhaled anti-asthma drugs? Thorax 1994;49:1090-5.
24. Ernst P, Spitzer WO, Suissa S, et al. Risk of fatal and nearfatal asthma in relation to inhaled corticosteroid use. JAMA 1992;268:3462-4.
25. Garrett JE, Turner P. The severity of asthma in relation to beta-agonist prescribing. N Z Med J 1991;104:39-40.
26. Pearce N, Grainger J, Atkinson M, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax 1990;45:170-5.
27. Crane J, Pearce N, Flatt A, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet 1989;1:917-22.
28. Robins JM, Gail MH, Lubin JH. More on "biased selection of controls for case-control analyses of cohort studies." Biometrics 1986;42:293-9.
29. Mauritsen B, Statistical and Epidemiology Research Corporation (SERC). EGRET reference manual. Seattle: SERC, 1991.
30. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989;79:340-9.
31. Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990;142:832-6.
32. van Essen-Zandvliet EE, Hughes MD, Waalkens HJ, et al. Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. Am Rev Respir Dis 1992;146:547-54.
33. Strand LM, West R. Health data bases in Saskatchewan. In: Strom B, ed. Pharmacoepidemiology: the sciences of postmarketing drug surveillance. New York: Churchill-Livingstone, 1989:189-200.
34. West R. Saskatchewan Health data bases: a developing resource. Am J Prev Med 1988;4:25-7.
35. Malcom E, Downey W, Strand LM, et al. Saskatchewan Health's linkable data bases and pharmacoepidemiology. Post Marketing Surveillance 1993;6:175-264.
36. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research: principles and quantitative methods. New York: Van Nostrand Reinhold Company, 1982.
37. Ernst P, Fitzgerald JM, Spier S. Canadian asthma consensus conference: summary of recommendations. Can Respir J 1996;3:89-100.